Health News

WASHINGTON (MedPage Today) — The Food and Drug Administration turned down a request for accelerated approval of Roche-Genentech’s trastuzumab-DM1 for treatment of HER2-positive breast cancer.

Read more

Filed under: General Health News
Tags: Breast Cancer, cancer, Drug, General Health News

Related posts

• Traces of CA Drug Prompts Muscle Builder Recall (0)
  WASHINGTON (MedPage Today) -- Makers of the supplement ArimaDex -- advertised to boost testosterone and build lean muscle mass — voluntarily recalled the product after traces of an aromatase inhibitor used in the treatment of breast cancer was found in an FDA analysis. Read more [tags] General Health News [/tags]
  
  
• Study identifies causes of bone loss in breast cancer survivors (0)
  (Loyola University Health System) Osteoporosis is a growing concern among breast cancer survivors and their doctors because certain cancer drugs can cause bone loss. But a new study has found that cancer drugs aren't the only culprits. Among 64 breast cancer patients referred to a bone health clinic, 78 percent had at least one other [...]
  
  
• Researchers identify new protein that triggers breast cancer (0)
  (University of Montreal) Canadian researchers have identified a new protein in the progression of breast cancer. According to a recent study from the Universite de Montreal and the University of Alberta, published in the Journal of Biological Chemistry, the protein ARF1 plays a critical role in cancer cell growth and the spread of tumors. Targeting [...]
  
  
• New Bevacizumab Data Fails to Support Use in Advanced Breast CA (0)
  WASHINGTON (MedPage Today) -- Adding bevacizumab (Avastin) to chemotherapy drugs doesn't increase survival or improve symptoms for women with advanced breast cancer, according to FDA documents posted in advance of an advisory panel meeting on Tuesday. Read more [tags] General Health News [/tags]
  
  
• Meta-analyses of global trials finds in favor of aromatase inhibitors (0)
  (Mayo Clinic) Two separate meta-analyses of clinical trials from around the world that tested tamoxifen against aromatase inhibitor drugs in postmenopausal women with early breast cancer have each reached the same conclusion: aromatase inhibitors are more effective in preventing breast cancer from coming back. Patients using aromatase inhibitors had more than a 3 percent lower [...]